Clinical Trial: A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta(R) After a Single 600 mg SC Injection in Healthy Male Volunteers

U.S., Dec. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07299955) titled 'A Phase 1 Comparative Study to Evaluate Pharmacokinetics, Immunogenicity, Safety and Tolerability of Bmab3000 and Herceptin Hylecta(R) After a Single 600 mg SC Injection in Healthy Male Volunteers' on Dec. 10.

Brief Summary: This phase I study is to compare the pharmacokinetics (PK), immunogenicity, safety, and tolerability of Bmab3000 (test) and Herceptin Hylecta (reference) after a single subcutaneous (s.c.) dose in healthy male volunteers.

Study Start Date: Jan. 09, 2026

Study Type: INTERVENTIONAL

Condition: Healthy Male Participants

Intervention: BIOLOGICAL: Bmab3000

Single s.c. dose of Bmab3000 containing 600 mg of trast...